Revenue decline and GAAP loss are negative, but the adjusted EPS beat and narrowed guidance (higher low end) suggest stabilization. Watch for Q4 revenue trajectory and 2027 guidance for signs of recovery from coding headwinds; the 2028 CPT code change is a long-term catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $61.90entry
- T+1 · 13d ago +7.61%α +5.96% · $66.61
- T+5 · 7d ago +0.66%α +1.25% · $62.31
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Inspire Medical Systems reported Q3 2026 revenue of $206.7M, down 7.9% YoY, and adjusted diluted EPS of $0.14, beating the consensus estimate of $0.09. The company narrowed its full-year 2026 revenue guidance to $850M-$860M (from $835M-$875M) and maintained adjusted EPS guidance of $1.20-$1.40. Revenue decline was driven by coding and reimbursement headwinds, partially offset by higher-margin Inspire V mix and a new CPT code approval for 2028.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $206.7M, down 7.9% YoY from $224.5M
- GAAP diluted EPS $(0.84); adjusted diluted EPS $0.14 (consensus $0.09, beat)
- Operating loss $(28.7M); adjusted operating income $1.9M (0.9% margin)
- Net loss $(24.4M) vs net earnings $9.9M in Q3 2025
- Operating cash flow $46.4M, down from $68.5M YoY
- Full-year 2026 revenue guidance narrowed to $850M-$860M (prior $835M-$875M)
- Adjusted diluted EPS guidance maintained at $1.20-$1.40
- AMA approved new Category I CPT code for single lead HGNS (Inspire V), effective Jan 1, 2028
- Restructuring charges of $24.1M related to Project Horizon
- Legal settlement expense of $7.0M for pixel-tracking class action
Financial Impact
Revenue decline of $17.8M YoY; adjusted EPS beat consensus by $0.05 (55.6% surprise); restructuring charges $24.1M; legal settlement $7.0M
Risk Factors
- Revenue declined 7.9% YoY due to coding and reimbursement challenges
- GAAP net loss of $(24.4M) vs prior-year profit
- Restructuring charges of $24.1M and legal settlement of $7.0M weigh on profitability
- Operating cash flow declined 32% YoY
- Full-year guidance implies Q4 revenue of $238M-$248M, requiring acceleration
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393767 |
Track record
16 reports on INSP
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $59.52 Now $59.12 −0.67% settles Nov 17
- Nov 12, 20264d ago SC 13G/A Bearish 4/10 Entry $60.54 to $61.10 Now $59.12 +2.35% ▼ −0.93% −1.29% vs SPY
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $62.31 to $62.11 Now $59.12 −5.12% ▼ −0.32% −1.64% vs SPY
- Nov 9, 20267d ago SC 13G/A Bearish 4/10 Entry $62.31 to $62.11 Now $59.12 +5.12% ▲ +0.32% +1.64% vs SPY
- Nov 2, 202614d ago 8-K Mixed 6/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Viewing Entry $61.90 to $66.61 Now $59.12 −4.49% ▲ +7.61% +5.96% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $68.10 to $67.21 Now $59.12 −13.19% ▼ −1.31% −0.83% vs SPY
- Oct 5, 20266w ago Press Release Neutral 1/10 Entry $68.20 Now $59.12 −13.31% No price data
- Jul 27, 202616w ago 3 Neutral 1/10 Entry $51.97 to $51.07 Now $59.12 +13.76% ▼ −1.73% −0.19% vs SPY
- Jul 24, 202616w ago 8-K Neutral 2/10 Entry $50.93 to $51.97 Now $59.12 +16.08% ▲ +2.04% +1.80% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers